



## **FOR IMMEDIATE RELEASE**

Tokyo, June 14, 2023

### **JT's License Partner Salubris Announced that Enarodustat, a HIF-PH Inhibitor, Received Regulatory Approval in Mainland China**

Japan Tobacco Inc. (JT) (TSE:2914) announced today that Shenzhen Salubris Pharmaceuticals Co., Ltd. ("Salubris") issued a statement its product Enarodustat tablets (恩那罗®), a hypoxia inducible factor prolyl hydroxylase ("HIF-PH") inhibitor, was approved by the National Medical Products Administration of China for the treatment of Anemia Associated with Chronic Kidney Disease ("CKD") in adult patients not on dialysis on June 7, 2023.

In accordance with the exclusive license agreement for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan, JT licensed Enarodustat to Salubris in December 25, 2019.

In 2020, Enarodustat, discovered and developed by JT, was approved and launched for the treatment of anemia associated with CKD in Japan.

JT expects Enarodustat tablets to be a new therapeutic option for Anemia Associated with CKD in adult patients not on dialysis in Mainland China.

#### **About Enarodustat**

Enarodustat is an orally active HIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin ("EPO") and controlling the expression of molecules responsible for iron metabolism.

#### **About Anemia Associated with CKD**

Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.

###

*Japan Tobacco Inc. is a leading international tobacco company and our products are sold in over 130 markets. With approximately 53,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.*

Contact: Ichiro Kawai, Director  
Manabu Hirose, Associate Manager  
Media and Investor Relations Division  
Japan Tobacco Inc.  
Tokyo: +81-3-6636-2914  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)